ClinConnect ClinConnect Logo
Search / Trial NCT06128824

High Frequency Imaging in Cerebral Amyloid Angiopathy

Launched by MARTIN DICHGANS · Nov 7, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Cortical Superficial Siderosis Dwi+ Lesion Serial Imaging Disease Progression Mri Cerebrovascular Events Focal Subarachnoid Hemorrhage

ClinConnect Summary

The HIFI-CAA study is investigating a condition called cerebral amyloid angiopathy (CAA), which is common in older adults and can lead to serious problems like brain bleeding, disability, and memory issues. The researchers want to learn more about specific brain changes in CAA patients, particularly a type of brain bleeding known as cortical superficial siderosis (cSS) and other related lesions. By using advanced imaging techniques every month, they hope to understand how these changes happen and what they mean for patients' health.

To join this study, participants need to be diagnosed with probable CAA and show certain signs like cSS or previous brain bleeding in specific areas. They should not have bleeding in deeper parts of the brain or other conditions that could cause similar symptoms. Participants will attend regular MRI scans to monitor their brain health over time. This study is important because it aims to improve understanding of CAA, which could lead to better treatments for those affected.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Probable CAA according to the modified Boston criteria with evidence of
  • 1. cSS or fSAH
  • 2. lobar ICH survivors without cSS or fSAH
  • Absence of ICH or microbleed in deep locations (basal ganglia, thalamus, brain stem)
  • Absence of infratentorial siderosis or infratentorial SAH
  • MR-/CT-/DS-angiography without evidence of cerebral aneurysm, AVM, AV-fistula or other possible etiology for the observed haemorrhagic manifestations
  • No history of head trauma resulting in loss of consciousness or radiologically visible traumatic brain injury
  • Written informed consent by patient herself/himself prior to study enrolment
  • Exclusion Criteria:
  • Unwillingness to participate in high-frequency (monthly) follow-up
  • Severe medical condition with expected life expectancy \<1 year
  • Contraindications for MRI (following local guidelines of the respective study center)

About Martin Dichgans

Martin Dichgans is a distinguished clinical trial sponsor known for its commitment to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong focus on neurology and related fields, the organization collaborates closely with academic institutions and healthcare professionals to design and execute clinical studies that adhere to the highest ethical and scientific standards. Martin Dichgans leverages cutting-edge methodologies and a patient-centered approach to contribute valuable insights to the medical community, ultimately aiming to enhance treatment options and quality of life for individuals affected by neurological disorders.

Locations

Bonn, , Germany

Magdeburg, , Germany

Munich, , Germany

Patients applied

0 patients applied

Trial Officials

Marco Duering, MD

Principal Investigator

Institute for Stroke and Dementia Research

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported